Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

Yanyun Gu; Xiaokai Wang; Junhua Li; Yifei Zhang; Huanzi Zhong; Ruixin Liu; Dongya Zhang; Qiang Feng; Xiaoyan Xie; Jie Hong; Huahui Ren; Wei Liu; Jing Ma; Qing Su; Hongmei Zhang; Jialin Yang; Xiaoling Wang; Xinjie Zhao; Weiqiong Gu; Yufang Bi; Yongde Peng; Xiaoqiang Xu; Huihua Xia; Fang Li; Xun Xu; Huanming Yang; Guowang Xu; Lise Madsen; Karsten Kristiansen; Guang Ning; Weiqing Wang

doi:10.1038/s41467-017-01682-2

Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

Yanyun Gu
, Xiaokai Wang
, Junhua Li
, Yifei Zhang
, Huanzi Zhong
, Ruixin Liu
, Dongya Zhang
, Qiang Feng
, Xiaoyan Xie
, Jie Hong
, Huahui Ren
, Wei Liu
, Jing Ma
, Qing Su
, Hongmei Zhang
, Jialin Yang
, Xiaoling Wang
, Xinjie Zhao
, Weiqiong Gu
, Yufang Bi

Yongde Peng, Xiaoqiang Xu, Huihua Xia, Fang Li, Xun Xu, Huanming Yang, Guowang Xu, Lise Madsen, Karsten Kristiansen, Guang Ning, Weiqing Wang

Shanghai Institute for Endocrine and Metabolic Diseases
BGI-Shenzhen
University of Chinese Academy of Sciences
University of Copenhagen
Shanghai Jiao Tong University
Shanghai Minhang District Central Hospital
CAS - Dalian Institute of Chemical Physics
Zhejiang University
Institute of Marine Research

科研成果: 期刊稿件 › 文章 › 同行评审

358 引用（Scopus）

摘要

Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.

源语言	英语
文章编号	1785
期刊	Nature Communications
卷	8
期	1
DOI	https://doi.org/10.1038/s41467-017-01682-2
出版状态	已出版 - 1 12月 2017
已对外发布	是

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

可持续发展目标 3 良好健康与福祉

访问文件

10.1038/s41467-017-01682-2

其它文件与链接

链接到 Scopus 的出版物

引用此

Gu, Y., Wang, X., Li, J., Zhang, Y., Zhong, H., Liu, R., Zhang, D., Feng, Q., Xie, X., Hong, J., Ren, H., Liu, W., Ma, J., Su, Q., Zhang, H., Yang, J., Wang, X., Zhao, X., Gu, W., ... Wang, W. (2017). Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment. Nature Communications, 8(1), 文章 1785. https://doi.org/10.1038/s41467-017-01682-2

@article{2128e29f872f47929666b66150fcf446,

title = "Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment",

abstract = "Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.",

author = "Yanyun Gu and Xiaokai Wang and Junhua Li and Yifei Zhang and Huanzi Zhong and Ruixin Liu and Dongya Zhang and Qiang Feng and Xiaoyan Xie and Jie Hong and Huahui Ren and Wei Liu and Jing Ma and Qing Su and Hongmei Zhang and Jialin Yang and Xiaoling Wang and Xinjie Zhao and Weiqiong Gu and Yufang Bi and Yongde Peng and Xiaoqiang Xu and Huihua Xia and Fang Li and Xun Xu and Huanming Yang and Guowang Xu and Lise Madsen and Karsten Kristiansen and Guang Ning and Weiqing Wang",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41467-017-01682-2",

language = "英语",

volume = "8",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Gu, Y, Wang, X, Li, J, Zhang, Y, Zhong, H, Liu, R, Zhang, D, Feng, Q, Xie, X, Hong, J, Ren, H, Liu, W, Ma, J, Su, Q, Zhang, H, Yang, J, Wang, X, Zhao, X, Gu, W, Bi, Y, Peng, Y, Xu, X, Xia, H, Li, F, Xu, X, Yang, H, Xu, G, Madsen, L, Kristiansen, K, Ning, G & Wang, W 2017, 'Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment', Nature Communications, 卷 8, 号码 1, 1785. https://doi.org/10.1038/s41467-017-01682-2

TY - JOUR

T1 - Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

AU - Gu, Yanyun

AU - Wang, Xiaokai

AU - Li, Junhua

AU - Zhang, Yifei

AU - Zhong, Huanzi

AU - Liu, Ruixin

AU - Zhang, Dongya

AU - Feng, Qiang

AU - Xie, Xiaoyan

AU - Hong, Jie

AU - Ren, Huahui

AU - Liu, Wei

AU - Ma, Jing

AU - Su, Qing

AU - Zhang, Hongmei

AU - Yang, Jialin

AU - Wang, Xiaoling

AU - Zhao, Xinjie

AU - Gu, Weiqiong

AU - Bi, Yufang

AU - Peng, Yongde

AU - Xu, Xiaoqiang

AU - Xia, Huihua

AU - Li, Fang

AU - Xu, Xun

AU - Yang, Huanming

AU - Xu, Guowang

AU - Madsen, Lise

AU - Kristiansen, Karsten

AU - Ning, Guang

AU - Wang, Weiqing

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.

AB - Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary BAs and plasma levels of unconjugated BAs in treatment-naive type 2 diabetes (T2D) patients, which may beneficially affect metabolism. Acarbose increases the relative abundances of Lactobacillus and Bifidobacterium in the gut microbiota and depletes Bacteroides, thereby changing the relative abundance of microbial genes involved in BA metabolism. Treatment outcomes of Acarbose are dependent on gut microbiota compositions prior to treatment. Compared to patients with a gut microbiota dominated by Prevotella, those with a high abundance of Bacteroides exhibit more changes in plasma BAs and greater improvement in metabolic parameters after Acarbose treatment. Our work highlights the potential for stratification of T2D patients based on their gut microbiota prior to treatment.

UR - https://www.scopus.com/pages/publications/85035341770

U2 - 10.1038/s41467-017-01682-2

DO - 10.1038/s41467-017-01682-2

M3 - 文章

C2 - 29176714

AN - SCOPUS:85035341770

SN - 2041-1723

VL - 8

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1785

ER -

Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

摘要

联合国可持续发展目标

访问文件

其它文件与链接

学术指纹

引用此